within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC58_DecitabineCombinations;

model DecitabineCombinations
  extends Pharmacolibrary.Drugs.ATC.L.L01BC58;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01BC58</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Decitabine is a nucleoside analog of cytidine with antineoplastic activity, primarily used in the treatment of myelodysplastic syndromes and acute myeloid leukemia (AML). It functions as a DNA methyltransferase inhibitor, resulting in hypomethylation of DNA and restoring normal gene function in cancer cells. Decitabine, in combination with other agents, may be considered in hematological malignancies. It is an approved drug and is currently in clinical use for certain hematologic cancers.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients (both sexes), primarily with AML or MDS, following intravenous administration of decitabine, alone or in combination regimens.</p><h4>References</h4><ol><li><p>Garcia-Manero, G, et al., &amp; Savona, MR (2024). Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. <i>The Lancet. Haematology</i> 11(1) e15–e26. DOI:<a href=&quot;https://doi.org/10.1016/S2352-3026(23)00338-1&quot;>10.1016/S2352-3026(23)00338-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38135371/&quot;>https://pubmed.ncbi.nlm.nih.gov/38135371</a></p></li><li><p>Geissler, K, et al., &amp; Lübbert, M (2024). Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. <i>British journal of haematology</i> 205(5) 1734–1745. DOI:<a href=&quot;https://doi.org/10.1111/bjh.19741&quot;>10.1111/bjh.19741</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39313917/&quot;>https://pubmed.ncbi.nlm.nih.gov/39313917</a></p></li><li><p>Bouligny, IM, &amp; DiNardo, CD (2024). Oral decitabine-cedazuridine in acute myeloid leukaemia. <i>British journal of haematology</i> 205(5) 1674–1676. DOI:<a href=&quot;https://doi.org/10.1111/bjh.19769&quot;>10.1111/bjh.19769</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39313925/&quot;>https://pubmed.ncbi.nlm.nih.gov/39313925</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end DecitabineCombinations;
